JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

Search

Eli Lilly and Co.

Slēgts

SektorsVeselības aprūpe

696.49 -1.99

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

694.22

Max

712.89

Galvenie mērījumi

By Trading Economics

Ienākumi

2.9B

5.7B

Pārdošana

2.8B

16B

P/E

Sektora vidējais

45.864

35.473

EPS

6.31

Dividenžu ienesīgums

0.8

Peļņas marža

36.384

Darbinieki

47,000

EBITDA

3.3B

7.5B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+31.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.80%

2.38%

Nākamie ieņēmumi

2025. g. 30. okt.

Nākamais dividenžu datums

2025. g. 10. sept.

Nākamais Ex dividenžu datums

2025. g. 14. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-62B

629B

Iepriekšējā atvēršanas cena

698.48

Iepriekšējā slēgšanas cena

696.49

Ziņu noskaņojums

By Acuity

38%

62%

136 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 25. aug. 15:59 UTC

Galvenie tirgus virzītāji

Immuneering Shares Climb On Supply Agreement with Eli Lilly

2025. g. 7. aug. 11:36 UTC

Peļņas

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

2025. g. 12. aug. 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

2025. g. 8. aug. 19:34 UTC

Tirgus saruna

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

2025. g. 8. aug. 05:32 UTC

Tirgus saruna

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

2025. g. 7. aug. 16:20 UTC

Peļņas

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

2025. g. 7. aug. 14:18 UTC

Tirgus saruna
Peļņas

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

2025. g. 7. aug. 13:54 UTC

Peļņas

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

2025. g. 7. aug. 12:12 UTC

Peļņas

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

2025. g. 7. aug. 11:58 UTC

Peļņas

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

2025. g. 7. aug. 11:32 UTC

Peļņas

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 11:03 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025. g. 7. aug. 10:49 UTC

Peļņas

Eli Lilly 2Q Gross Margin 84.3% >LLY

2025. g. 7. aug. 10:48 UTC

Peļņas

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

2025. g. 7. aug. 10:47 UTC

Peļņas

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

2025. g. 7. aug. 10:46 UTC

Peļņas

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

2025. g. 7. aug. 10:46 UTC

Peļņas

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

2025. g. 7. aug. 10:46 UTC

Peļņas

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

2025. g. 7. aug. 10:45 UTC

Peļņas

Eli Lilly 2Q Net $5.66B >LLY

2025. g. 7. aug. 10:45 UTC

Peļņas

Eli Lilly 2Q Rev $15.56B >LLY

2025. g. 7. aug. 10:45 UTC

Peļņas

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

2025. g. 7. aug. 10:41 UTC

Peļņas

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

2025. g. 6. aug. 20:34 UTC

Peļņas

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

2025. g. 6. aug. 08:45 UTC

Peļņas

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

2025. g. 30. jūl. 10:38 UTC

Tirgus saruna

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

2025. g. 29. jūl. 17:05 UTC

Peļņas

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

2025. g. 29. jūl. 16:55 UTC

Peļņas

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

2025. g. 29. jūl. 13:35 UTC

Peļņas

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

2025. g. 29. jūl. 11:39 UTC

Peļņas

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

2025. g. 25. jūl. 12:49 UTC

Iegādes, apvienošanās, pārņemšana

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

31.86% augšup

Prognoze 12 mēnešiem

Vidējais 938.39 USD  31.86%

Augstākais 1,190 USD

Zemākais 700 USD

Pamatojoties uz 22 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

22 ratings

17

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 884.54Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

136 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.